{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:12:54Z","timestamp":1792732374796,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA0-08748"],"award-info":[{"award-number":["P30-CA0-08748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01AR077511"],"award-info":[{"award-number":["U01AR077511"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR074530"],"award-info":[{"award-number":["K23AR074530"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jaad.2020.04.105","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T20:40:05Z","timestamp":1588106405000},"page":"1130-1143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features"],"prefix":"10.1016","volume":"83","author":[{"given":"Samantha R.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aren T.","family":"Vierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian W.","family":"Millsop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Kiuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.04.105_bib1","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaad.2020.04.105_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib5","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1007\/s00262-005-0092-8","article-title":"CD4(+)CD25high regulatory T cells increase with tumor stage in patients with\u00a0gastric and esophageal cancers","volume":"55","author":"Kono","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaad.2020.04.105_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2020.04.105_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2020.04.105_bib9","first-page":"588","article-title":"Technology evaluation: ipilimumab, Medarex\/Bristol-Myers Squibb","volume":"7","author":"Morse","year":"2005","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.jaad.2020.04.105_bib10","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"Embo J"},{"key":"10.1016\/j.jaad.2020.04.105_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2020.04.105_bib12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2020.04.105_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1212631","article-title":"At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy","volume":"94","author":"Callahan","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaad.2020.04.105_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaad.2020.04.105_bib17","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2020.04.105_bib18","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib19","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for\u00a0metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.seminoncol.2015.02.010","article-title":"Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies","volume":"42","author":"Eggermont","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of\u00a0PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib22","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib30","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib31","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib32","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","author":"Kanz","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib34","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib36","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.04.105_bib38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib39","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib41","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib42","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib43","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2020.04.105_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ijd.13540","article-title":"Histopathological aspects of cutaneous erythematous-papular eruptions induced by\u00a0immune checkpoint inhibitors for the treatment of metastatic melanoma","volume":"56","author":"Perret","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib46","doi-asserted-by":"crossref","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al. CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. doi: 10.1016\/j.jaad.2020.03.132. Published online May 23, 2020.","DOI":"10.1016\/j.jaad.2020.03.132"},{"key":"10.1016\/j.jaad.2020.04.105_bib47","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in\u00a0patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib48","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2020.04.105_bib49","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2020.04.105_bib50","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3747\/co.20.1265","article-title":"Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases","volume":"20","author":"Assi","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/DAD.0000000000000587","article-title":"Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without ipilimumab","volume":"39","author":"Chou","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib53","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib57","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib59","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib61","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1600-0714.2010.00946.x","article-title":"Pathogenesis of oral lichen planus\u2014a review","volume":"39","author":"Roopashree","year":"2010","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2015.03.001","article-title":"Clinical perspectives and murine models of lichenoid tissue reaction\/interface dermatitis","volume":"78","author":"Okiyama","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2020.04.105_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jdcr.2016.06.012","article-title":"Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma","volume":"2","author":"Mutgi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.04.105_bib64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2020.04.105_bib67","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib68","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib70","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000492172","article-title":"Atezolizumab-induced Stevens-Johnson Syndrome in a patient with non-small cell lung carcinoma","volume":"10","author":"Chirasuthat","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib71","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib72","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CJI.0000000000000121","article-title":"Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC)","volume":"39","author":"Chia","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2020.04.105_bib73","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer","volume":"55","author":"Law-Ping-Man","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.04.105_bib74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/1346-8138.13450","article-title":"Case of de novo psoriasis possibly triggered by nivolumab","volume":"44","author":"Murata","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib76","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib77","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.04.105_bib78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apm.12658","article-title":"Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome","volume":"125","author":"Ruiz-Banobre","year":"2017","journal-title":"APMIS"},{"key":"10.1016\/j.jaad.2020.04.105_bib79","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib80","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","volume":"30","author":"Kato","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.04.105_bib81","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for\u00a0metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.04.105_bib82","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2020.04.105_bib83","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/bjd.13058","article-title":"First report of ipilimumab-induced Grover disease","volume":"171","author":"Munoz","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib84","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-016-0157-6","article-title":"A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1","volume":"4","author":"Uemura","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib85","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-016-0151-z","article-title":"Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib86","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4065\/74.3.229","article-title":"Grover's disease: clinicopathologic review of 72 cases","volume":"74","author":"Davis","year":"1999","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.jaad.2020.04.105_bib88","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cup.13150","article-title":"Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern","volume":"45","author":"Trinidad","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000161122","article-title":"Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient","volume":"218","author":"Eckert","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2020.04.105_bib90","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib91","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1183\/09031936.00107912","article-title":"Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy","volume":"41","author":"Tissot","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaad.2020.04.105_bib92","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jaad.2020.04.105_bib93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib94","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.04.105_bib95","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2020.04.105_bib96","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum D"},{"key":"10.1016\/j.jaad.2020.04.105_bib97","first-page":"418","article-title":"Scar sarcoidosis: a case report and brief review","volume":"78","author":"Selim","year":"2006","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2020.04.105_bib98","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00000372-200010000-00004","article-title":"Foreign bodies in sarcoidosis","volume":"22","author":"Kim","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib99","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CMR.0000000000000261","article-title":"Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib100","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jaad.2014.06.042","article-title":"Ipilimumab-associated Sweet syndrome in a melanoma patient","volume":"71","author":"Gormley","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib101","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jaad.2013.11.022","article-title":"Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma","volume":"70","author":"Kyllo","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib102","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib103","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1684\/ejd.2014.2297","article-title":"Neutrophilic disease of the skin and intestines after\u00a0ipilimumab treatment for malignant melanoma-simultaneous occurrence of pyoderma gangrenosum and colitis","volume":"24","author":"Rudolph","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib104","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjd.15193","article-title":"Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum","volume":"177","author":"Wu","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib106","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous\u00a0skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib107","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.04.105_bib108","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor","volume":"31","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.04.105_bib109","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1684\/ejd.2016.2959","article-title":"Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab","volume":"27","author":"Russo","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib112","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.04.105_bib113","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2020.04.105_bib114","first-page":"58","article-title":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies","volume":"1865","author":"Xia","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaad.2020.04.105_bib115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2020.04.105_bib116","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/jid.2010.427","article-title":"Genetic variants in CTLA4 are strongly associated with alopecia areata","volume":"131","author":"John","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib117","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1523-1747.2002.01811.x","article-title":"Gene\u00a0array profiling and immunomodulation studies define\u00a0a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans","volume":"119","author":"Carroll","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib118","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib119","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2017.2106","article-title":"Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer","volume":"153","author":"Rivera","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2020.04.105_bib121","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.04.105_bib122","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo\u00a0with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib123","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib124","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.156.6.1755","article-title":"Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets","volume":"156","author":"Houghton","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2020.04.105_bib125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjd.14474","article-title":"Extensive tumoral melanosis associated with ipilimumab-treated melanoma","volume":"175","author":"Staser","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib126","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2230.2012.04452.x","article-title":"Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases","volume":"38","author":"Libon","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib127","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib128","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00262-011-1011-9","article-title":"CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases","volume":"60","author":"Yuan","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaad.2020.04.105_bib129","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib130","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1111\/jdv.14503","article-title":"Eruptive keratoacanthomas arising in the setting of lichenoid\u00a0toxicity after programmed cell death 1 inhibition with nivolumab","volume":"32","author":"Feldstein","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.04.105_bib131","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2340\/00015555-2566","article-title":"Development of papulopustular rosacea during nivolumab therapy for metastatic cancer","volume":"97","author":"Bousquet","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.04.105_bib132","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/annonc\/mdw543","article-title":"Pembrolizumab induced severe sclerodermoid reaction","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.04.105_bib133","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1684\/ejd.2016.2770","article-title":"A case of drug-associated dermatomyositis following ipilimumab therapy","volume":"26","author":"Yamaguchi","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2020.04.105_bib134","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/CMR.0000000000000191","article-title":"Acute skin reaction suggestive of pembrolizumab-induced radiosensitization","volume":"25","author":"Sibaud","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2020.04.105_bib135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ijd.13833","article-title":"Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade","volume":"58","author":"Mauzo","year":"2019","journal-title":"Int J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220307210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220307210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:36:09Z","timestamp":1777523769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220307210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":135,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0190962220307210"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.105","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}